Form 4: Nektar Therapeutics Executive Trades NKTR Shares
Statement of Changes in Beneficial Ownership
Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky reported a transaction involving Nektar Therapeutics common stock under a Rule 10b5-1 trading plan.
Summary
- Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics, executed a transaction involving the company's common stock.
- The transaction, dated June 30, 2026, involved the disposal of 5,681 shares of common stock at a price of $70 per share.
- Following this transaction, Zalevsky beneficially owns 9,756 shares of Nektar Therapeutics common stock.
- This trade was conducted under a Rule 10b5-1 trading plan established on March 13, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard insider transaction executed under a pre-established trading plan, without indicating new company performance or strategic shifts.
Future Outlook
No specific future outlook or guidance is provided in this filing, as it pertains to a single insider transaction.
Industry Context
StockSavvy.ai notes that Form 4 filings, such as this one from Nektar Therapeutics, are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan indicates pre-planned trading activity by executives, often used to diversify holdings or manage personal finances while adhering to insider trading regulations.
Key Dates
| Date | Description |
|---|---|
| 03/13/2026 | Date Rule 10b5-1 trading plan was adopted by Jonathan Zalevsky. |
| 06/30/2026 | Transaction date for the disposal of Nektar Therapeutics common stock. |
| 07/02/2026 | Date of signature for the filing. |
Keywords
Nektar Therapeutics, NKTR, Form 4, Insider Trading, Rule 10b5-1, Stock Transaction, Executive Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.